Ropes & Gray Advised Foghorn Therapeutics in $50 Million Registered Direct Offering

Ropes & Gray Advised Foghorn Therapeutics in $50 Million Registered Direct Offering

Ropes & Gray represented Foghorn Therapeutics in its registered direct offering of 2,030,314 shares of common stock at $6.71 per share and to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of 5,421,250 shares of its common stock, along with additional warrants to purchase an aggregate of 7,451,564 shares of common stock for total gross proceeds of approximately $50 million. The closing was announced in a Jan.

Foghorn is a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression.

The team was led by capital markets partners Rachel Phillips (Partner/ Capital Markets) and Will Michener (Partner/ Capital Markets).

If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.